Compare GENC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GENC | ENGN |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Construction/Ag Equipment/Trucks | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.5M | 117.2M |
| IPO Year | 1995 | N/A |
| Metric | GENC | ENGN |
|---|---|---|
| Price | $15.24 | $1.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $17.60 | ★ $21.08 |
| AVG Volume (30 Days) | 28.7K | ★ 906.7K |
| Earning Date | 02-06-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.08 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.51 | N/A |
| P/E Ratio | $30.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.22 | $1.40 |
| 52 Week High | $17.40 | $12.25 |
| Indicator | GENC | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 38.41 |
| Support Level | $14.55 | $1.68 |
| Resistance Level | $15.62 | $1.85 |
| Average True Range (ATR) | 0.38 | 0.08 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 52.50 | 68.00 |
Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.